Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Co. is developing a fully human monoclonal antibody, IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor. IMVT-1401 has been observed to reduce immunoglobulin G (IgG) antibody levels. High levels of pathogenic IgG antibodies drive a variety of autoimmune diseases. Co. is developing IMVT-1401 as a fixed-dose, self-administered subcutaneous injection on a weekly, or less frequent, dosing schedule. The IMVT stock yearly return is shown above.
The yearly return on the IMVT stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the IMVT annual return calculation with any dividends reinvested as applicable (on ex-dates).
|